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Impact of Chronic Kidney
Disease on Platelet Function Profiles in
Diabetes Mellitus Patients With Coronary
Artery Disease Taking Dual Antiplatelet Therapy
Dominick J. Angiolillo, MD, PHD,* Esther Bernardo, BSC,† Davide Capodanno, MD,*
David Vivas, MD,† Manel Sabaté, MD, PHD,† José Luis Ferreiro, MD,* Masafumi Ueno, MD,*
Pilar Jimenez-Quevedo, MD, PHD,† Fernando Alfonso, MD, PHD,† Theodore A. Bass, MD,*
Carlos Macaya, MD, PHD,† Antonio Fernandez-Ortiz, MD, PHD†
Jacksonville, Florida; and Madrid, Spain
Objectives We sought to assess the impact of renal function on platelet reactivity in patients with diabetes mellitus (DM)
and coronary artery disease on aspirin and clopidogrel therapy.
Background Diabetes mellitus is a key risk factor for chronic kidney disease (CKD). In aspirin-treated DM patients the
presence of moderate/severe CKD is associated with reduced clinical efficacy of adjunctive clopidogrel ther-
apy. Whether these findings may be attributed to differences in clopidogrel-induced effects is unknown.
Methods This was a cross-sectional observational study in which DM patients taking maintenance aspirin and clopidogrel
therapy were studied. Patients were categorized into 2 groups according to the presence or absence of moder-
ate/severe CKD. Platelet aggregation after adenosine diphosphate (ADP) and collagen stimuli were assessed
with light transmittance aggregometry and defined patients with high post-treatment platelet reactivity (HPPR).
Markers of platelet activation, including glycoprotein IIb/IIIa activation and P-selectin expression, were also de-
termined using flow cytometry.
Results A total of 306 DM patients were analyzed. Patients with moderate/severe CKD (n  84) had significantly higher
ADP-induced (60  13% vs. 52  15%, p  0.001) and collagen-induced (49  20% vs. 41  20%, p  0.004)
platelet aggregation compared with those without (n  222). After adjustment for potential confounders, pa-
tients with moderate/severe CKD were more likely to have HPPR after ADP (adjusted odds ratio: 3.8, 95% confi-
dence interval: 1.7 to 8.5, p  0.001) and collagen (adjusted odds ratio: 2.4; 95% confidence interval: 1.1 to
5.4; p  0.029) stimuli. Markers of platelet activation were significantly increased in patients with HPPR.
Conclusions In DM patients with coronary artery disease taking maintenance aspirin and clopidogrel therapy, impaired renal
function is associated with reduced clopidogrel-induced antiplatelet effects and a greater prevalence of
HPPR. (J Am Coll Cardiol 2010;55:1139–46) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.043(
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fhronic kidney disease (CKD) is estimated to affect a sub-
tantial proportion of persons aged 65 and older worldwide and
s recognized as an independent predictor of myocardial in-
arction (MI), stroke, and all-cause mortality (1–4). Impor-
antly, patients with CKD experience an increased risk of
dverse outcomes after percutaneous coronary intervention
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rom placebo-controlled trials suggest that renal function
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Clopidogrel Effects and Renal Function in Diabetes March 16, 2010:1139–46CKD patients might have reduced
clopidogrel-induced antiplatelet
effects.
Type 2 diabetes mellitus (DM) is
a key risk factor for CKD (17–19)
and accounts for nearly one-half
of end-stage renal disease cases
in the U.S. (20). Several studies
have shown DM to be associated
with reduced clopidogrel response
(21–25). However, whether renal
function is associated with varia-
tions in clopidogrel-induced anti-
platelet effects within the DM
population remains unexplored.
The aim of the present study was
to assess the impact of renal func-
tion on pharmacodynamic profiles
in aspirin-treated DM patients
ith coronary artery disease (CAD) taking adjunctive clopi-
ogrel therapy.
ethods
atient population. This is a cross-sectional observational
tudy in which platelet function was assessed in medically
reated (taking oral hypoglycemic medication and/or insu-
in) type 2 DM patients with stable CAD. Type 2 DM was
efined according to the World Health Organization Re-
ort (26). All patients had angiographically documented
AD, because they had all previously undergone PCI.
atients were recruited at the outpatient clinic on the
ccasion of pre-scheduled follow-up visits at the interven-
ional cardiology unit of the San Carlos University Hospital
rom April 2003 to April 2007. Patients were eligible for
latelet function analyses if they were in their maintenance
teady-state phase (at least 30 days) of dual antiplatelet
herapy with aspirin (100 mg/day) and clopidogrel (75
g/day). A total of 1,103 diabetic patients were screened,
nd 419 were identified to be taking dual antiplatelet
herapy. Of the latter, 306 were eligible for the study. In the
emaining 113 patients, 1 or more of the exclusion criteria
ndicated in the following text were identified. The rationale
or assessing platelet function while patients were in their
aintenance phase of treatment for at least 30 days was to
vercome the variability in pharmacodynamic profiles
nown to occur during the initial days and weeks after
nitiation of therapy (27). The CKD was defined according
o the National Kidney Foundation Classification as follows
28): normal renal function (creatinine clearance 90 ml/
in), mild CKD (creatinine clearance 60 to 89 ml/min),
oderate CKD (creatinine clearance 30 to 59 ml/min), and
evere CKD (creatinine clearance 30 ml/min). Creatinine
learance was calculated according to the Cockroft-Gault
ormula (28). Due to the limited number of patients with
evere CKD, these patients were combined with moderate
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
CAD  coronary artery
disease
CI  confidence interval
CKD  chronic kidney
disease
DM  diabetes mellitus
HPPR  high post-
treatment platelet
reactivity
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary interventionKD patients into 1 group (moderate/severe CKD: creat- gnine clearance 60 ml/min). In the present analysis,
atients were first categorized into 2 groups according to the
resence or absence of moderate/severe CKD. This is also
n agreement with clinical studies showing that differences
n outcomes in patients taking dual antiplatelet therapy were
n those with advanced renal disease (10,12–16). Analyses
ere also performed across 3 groups (normal renal function,
ild CKD, and moderate/severe CKD) in order to assess
inearity in the impact of renal function on platelet function
rofiles.
Exclusion criteria included: known allergies to aspirin or
lopidogrel; type 2 DM without pharmacological treatment;
estational diabetes; dialysis; blood dyscrasia; active bleed-
ng or bleeding diathesis; gastrointestinal bleed within last 6
onths; hemodynamic instability; acute coronary or cere-
rovascular event within 3 months; any malignancy; con-
omitant use of other antithrombotic drugs (oral anticoagu-
ants, dypiridamole, cilostazol, ticlopidine) or nonsteroid
nti-inflammatory drugs; recent treatment (30 days) with
glycoprotein IIb/IIIa antagonist; platelet count 100 
06/l; hematocrit 25%; and liver disease (bilirubin level
2 mg/dl). The study complied with the Declaration of
elsinki, and all patients gave their informed written
onsent.
latelet function testing. Blood sampling for platelet
unction analyses were collected from an antecubital vein
ith a 21-gauge needle 2 to 4 h after antiplatelet drug
ntake. The first 2 to 4 ml of blood were discarded to avoid
pontaneous platelet activation, and samples were processed
ithin 1 h. Platelet function was assessed with light trans-
ittance aggregometry to assess platelet aggregation and
ow cytometry technique to assess markers of platelet
ctivation. Details of these assays are described elsewhere
21,23,27,29–31). In brief, platelet aggregation with light
ransmittance aggregometry was assessed with platelet-rich
lasma by the turbidimetric method in a 2-channel aggre-
ometer (Chrono-Log 490 Model, Chrono-Log Corp.,
avertown, Pennsylvania) according to standard protocols
21,23,27,29-31). Platelet-rich plasma was obtained as a
upernatant after centrifugation of citrated blood at 800 rpm
or 10 min. Platelet-poor plasma was obtained by a second
entrifugation of the blood fraction at 2,500 rpm for 10 min.
ight transmission was adjusted to 0% with platelet-rich
lasma and to 100% for platelet-rich plasma for each
easurement. Clopidogrel-induced antiplatelet effects were
ssessed after challenge with adenosine diphosphate (ADP)
20 mol/l). Nonpurinergic, mediated platelet aggregation
as assessed after collagen (6 g/ml) stimuli. Curves were
ecorded for 6 min, and maximal aggregation was measured.
istribution of platelet function profiles were analyzed, and
igh post-treatment platelet reactivity (HPPR) was defined
s the upper quartile of platelet aggregation, as previously
escribed (27,29,32). The association of renal function with
PPR to ADP (HPPRADP)-, collagen (HPPRCOLL)-, and
oth ADP and collagen (HPPRADPCOLL)-induced aggre-
ation was assessed.
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March 16, 2010:1139–46 Clopidogrel Effects and Renal Function in DiabetesMarkers of platelet activation were determined by assessing
latelet surface expression of activated glycoprotein IIb/IIIa
nd P-selectin with an Epics-XL Profile II Coulter flow
ytometer (Coulter Corp., Miami, Florida) as previously de-
cribed (29–31). The glycoprotein IIb/IIIa activation was
ssessed with (PAC-1 FICT conjugated; Becton Dickinson,
utherford, New Jersey) and polyclonal fluorescein
sothiocyanate-conjugated rabbit anti-human fibrinogen (800
mol/l, Dako Diagnostics, Glostrup, Denmark) antibodies.
he P-selectin expression was assessed with a phycoerythrin-
onjugated anti-CD62P (0.3 mg/ml, Becton Dickinson, San
osé, California). Platelet activation was expressed as the
ercentage of platelets positive for antibody binding.
tatistical analysis. Continuous variables were analyzed
or a normal distribution with the Shapiro-Wilk test.
ontinuous variables following a normal distribution are
resented as mean  SD and were compared with Student
npaired t test. One-way analysis of variance was used for
omparisons across quartiles and to generate p values for trend
ests. Variables not following a normal distribution are ex-
ressed as median (interquartile range) and were compared
ith Mann-Whitney rank-sum test. The Jonckheere-Terpstra
est was used for comparisons across quartiles and to generate
values for trend tests of non-normally distributed variables.
ategorical variables are presented as counts and percentages
nd were compared by means of the chi-square test or Fisher’s
xact test when at least 25% of values showed an expected cell
requency below 5. Control for potential confounders and
nalysis of independent correlates of HPPR were performed
ith a logistic regression model including age, gender, insulin-
ependent diabetes, obesity, smoking, dyslipidemia, hyperten-
ion, use of calcium antagonists, angiotensin-converting en-
yme inhibitors, beta-blockers, nitrates, lipophilic statins, and
roton pump inhibitors as independent control variables and
oderate/severe CKD as the independent study variable of
nterest. Odds ratio (OR) and 95% confidence interval (CI)
ere calculated. All probability values reported are 2-sided, and
value of p  0.05 was considered significant. Statistical
nalysis was performed with SPSS version 15.0 software
SPSS, Inc., Chicago, Illinois).
esults
atient population. A total of 306 type 2 DM patients were
tudied. Baseline demographic data, clinical characteristics, and
aboratory data of patients with (n  84) and without (n 
22) moderate/severe CKD are described in Table 1. Patients
ith moderate/severe CKD were more likely to be women,
lder, treated for multivessel CAD, and have lower body mass
ndex and lower hematocrit (Table 1).
latelet function profile analyses. In the overall study
opulation, maximal ADP-induced platelet aggregation was
4  15% and followed a normal bell-shaped distribution
ndicative of a broad variability in clopidogrel-induced
ntiplatelet effects (Fig. 1). Patients with moderate/severe iKD had significantly higher ADP-induced platelet aggre-
ation compared with those without (60  13% vs. 52 
5%, p  0.001). Platelet reactivity quartile cut points for
he 25th, 50th, and 75th percentiles of the study population
ere 44%, 56%, and 63%, respectively. The upper quartile
dentified patients with HPPRADP. The ADP-induced
ggregation was 35  9%, 51  3%, 59  2%, and 71 
%, from the lowest to highest quartile, respectively (p 
.001), and 71  7% versus 48  12% (p  0.001) in
atients with and without HPPRADP.
Collagen-induced aggregation was 43  20% in the
verall study population and was significantly higher in
atients with moderate/severe CKD compared with those
ithout (49  20% vs. 41  20%, p  0.004, respectively).
uartile cut points for the 25th, 50th, and 75th percentiles
ere 29%, 42%, and 59%, respectively. The upper quartile
aseline Demographic Data, Clinicalharacteristics, nd Labor tory Data Stratifiedccording to Renal Function
Table 1
Baseline Dem graphi Data, Clinical
Characteristics, and Laboratory Data Stratified
According to Renal Function
Creatinine Clearance
>60 ml/min
(n  222)
<60 ml/min
(n  84) p Value
Age (yrs) 63 10 72 8 0.001
Male 72.4 54.2 0.003
BMI (kg/m2) 30 4 28 4 0.001
Risk factors
Smoking 18.0 9.5 0.07
Hypertension 64.4 79.8 0.01
Dyslipidemia 68.5 70.2 0.76
Obesity (BMI 30 kg/m2) 45.5 32.9 0.06
Insulin-treated 26.6 32.1 0.33
Medical history
Prior MI 61.3 61.9 0.92
Prior stroke 2.3 3.6 0.69
Prior CABG 5.3 7.7 0.41
Symptomatic PAD 9.5 11.9 0.53
Multivessel CAD 61.5 80.2 0.002
Medical therapy
Beta-blockers 74.8 64.3 0.07
ACE inhibitors 59.9 63.1 0.61
Nitrates 36.5 40.5 0.52
Ca2 antagonists 25.6 32.8 0.27
Lipid-lowering agents
CYP 3A4 pathway metabolized 65.7 70.3 0.50
Non-CYP 3A4 pathway metabolized 5.4 6.3 0.76
Proton pump inhibitors 32.5 31.3 0.85
Laboratory data
Platelet count (1,000/mm3) 223 58 226 61 0.75
Hematocrit (%) 41 4 39 5 0.001
MPV (fl) 8.9 1.1 8.7 0.9 0.27
HbA1C (%) 7.1 1.2 7.0 1.4 0.91
Creatinine (g/dl) 0.9 0.2 1.3 0.5 0.001
alues are mean  SD or %.
ACE angiotensin-converting enzyme; BMI body mass index; CABG coronary artery bypass
raft surgery; CAD coronary artery disease; CYP 3A4 hepatic cytochrome P450 3A4; HbA1C
lycated hemoglobin A1C; MI  myocardial infarction; MPV  mean platelet volume; PAD 
eripheral artery disease.dentified patients with HPPRCOLL. Collagen-induced ag-
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Clopidogrel Effects and Renal Function in Diabetes March 16, 2010:1139–46regation was 17  8%, 37  4%, 51  5%, and 68  9%
rom the lowest to highest quartile, respectively (p 0.001),
nd 68  9% versus 35  15% (p  0.001) in patients with
nd without HPPRCOLL.
Figure 1 Interindividual Distribution of Platelet Aggregation
Stratified by Renal Function
Normal bell-shaped distribution of maximal adenosine diphosphate (ADP) (20
mol/l)-induced platelet aggregation in patients with normal or mildly impaired
renal function (A) and patients with moderate or severe chronic renal failure
(B) assessed at study entry. Shaded bars denote the distribution of patients
with high post-treatment platelet reactivity in the study groups.
latelet Activation Profiles According to HPPR StatusTable 2 Platelet Activation Profiles According to HPPR Status
HPPRADP
Yes No p Value Yes
Antifibrinogen 37 20 27 19 0.001 37 20
PAC-1 49 19 34 20 0.001 44 19
P-selectin 44 18 31 18 0.001 37 19
alues are mean  SD. High post-treatment platelet reactivity to ADP- (HPPRADP), collagen- (HPPR
ecton Dickinson, Rutherford, New Jersey).
ADP  adenosine disphosphate; COLL  collagen HPPR  high post-treatment platelet reactivity.Collagen-induced aggregation was higher (57  18% vs.
9  19%, p  0.001) in patients with and without
PPRADP. Similarly, ADP-induced aggregation was
igher (65 13% vs. 50 14%, p 0.001) in patients with
nd without HPPRCOLL. Among patients with HPPRADP,
7.9% had HPPRCOLL. Among patients with HPPRCOLL,
7.1% had HPPRADP. Patients with HPPRADPCOLL
14.4% of the total population) had significantly enhanced
DP- (74  8% vs. 51  13%, p 0.001) and collagen-
nduced (69  9% vs. 39  18%, p  0.001) platelet
ggregation. Markers of platelet activation were consistently
ncreased in patients with HPPRADP, HPPRCOLL, and
PPRADPCOLL (Table 2).
latelet function across different stages of CKD. Analy-
is of variance demonstrated significantly lower ADP- (p 
.001) and collagen-induced (p  0.016) platelet aggrega-
ion in patients with normal renal function compared with
hose with mild CKD and those with moderate/severe
KD (Fig. 2). However, no significant differences in
latelet aggregation were observed between patients with
ormal renal function and those with mild CKD (Fig. 2).
KD and HPPR. Patients with moderate/severe CKD
ere more likely to have HPPRADP than those without
oderate/severe CKD (35.7% vs. 20.8%, OR: 2.1, 95% CI:
.2 to 3.7, p  0.007). After adjustment for potential
onfounders, moderate/severe CKD remained significantly
ssociated with HPPRADP (adjusted OR: 3.8, 95% CI: 1.7
o 8.5, p  0.001). Intake of proton-pump inhibitors
adjusted OR: 2.78, 95% CI: 1.36 to 5.71, p  0.005) was
lso significantly associated with HPPRADP. Similarly,
igher rates of moderate/severe CKD were seen in patients
ith HPPRCOLL (33.3% vs. 22.1%; OR: 1.8; 95% CI: 1.0
o 3.1; p  0.043; adjusted OR: 2.4; 95% CI: 1.1 to 5.4;
 0.029) and in those with HPPRADPCOLL (23.8% vs.
0.8%; OR: 2.6; 95% CI: 1.3 to 5.0; p  0.004; adjusted
R: 3.3; 95% CI: 1.3 to 8.4; p  0.01) (Fig. 3).
iscussion
he present study demonstrates that in type 2 DM patients
ith CAD receiving maintenance aspirin and clopidogrel
herapy, the presence of moderate/severe CKD is associated
ith higher degrees of platelet reactivity compared with
atients with normal renal function/mild CKD. In partic-
HPPRCOLL HPPRADPCOLL
No p Value Yes No p Value
28 20 0.001 40 19 28 20 0.001
36 21 0.004 48 19 36 20 0.001
33 19 0.19 43 19 33 19 0.001
nd both ADP- and collagen-induced (HPPRADPCOLL) aggregation. PAC-1 (PAC-1 FICT conjugated;COLL), a
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March 16, 2010:1139–46 Clopidogrel Effects and Renal Function in Diabeteslar, after adjustment for potential confounders, patients
ith creatinine clearance 60 ml/min had an almost 4-fold
ncrease in the likelihood of showing high platelet reactivity
fter ADP stimuli and over a 2-fold increase in high platelet
eactivity after collagen stimuli. Importantly, these patients
ith high platelet aggregability also have increased markers
f platelet activation. Overall, these findings are indicative
ot only of dysfunctional purinergic signaling mediated
DP receptors but also of the presence of a hyper-reactive
latelet phenotype with upregulation of multiple signaling
athways. Therefore, these pharmacodynamic observations
Figure 2 Platelet Aggregation According to Renal Function
Box-and-whisker plot demonstrating post-treatment adenosine diphosphate
(ADP)-induced (A) and collagen-induced (B) platelet aggregation as measured
by light transmittance aggregometry in patients with creatinine clearance 90
ml/min (normal), 60 to 89 ml/min (mild chronic kidney disease [CKD]), and
60 ml/min (moderate/severe CKD) on chronic clopidogrel therapy. The cen-
tral box represents the values between the lower and upper quartiles, and the
middle line is the median. The vertical line extends to 1.5 interquartile ranges
from both ends of the box, excluding outliers (values more than 1.5 interquar-
tile ranges from the end of the box), which are displayed as separate points.ight explain the elevated prevalence of ischemic compli- sations, including stent thrombosis, among DM patients
ith advanced CKD.
Diabetes mellitus is the single most important cause of
KD (17–19). One year after successful PCI, mortality is
-fold higher in patients with moderate CKD and 12-fold
igher in patients with severe CKD than in those with
ormal renal function (6). The CKD patients also have
ore aggressive atherosclerotic disease and a greater risk of
hrombotic complications, including stent thrombosis
5,7,8,10–14). Therefore, it might be expected that CKD
atients are more likely to derive enhanced benefit from
herapeutic approaches shown to improve cardiovascular
utcomes in high-risk patients, including more potent
ntiplatelet treatment regimens as with adjunctive clopi-
ogrel therapy. However, a post hoc analysis of the
REDO (Clopidogrel for the Reduction of Events During
bservation) trial showed that, although long-term clopi-
ogrel use in patients with normal renal function resulted in
significant reduction in major adverse cardiovascular
vents at 28 days and 1 year, this benefit was less apparent
n mild CKD and not apparent at all in moderate CKD
atients (15). More recently, a post hoc analysis of the
HARISMA (Clopidogrel for High Atherothrombotic
isk and Ischemic Stabilization, Management, and Avoid-
nce) trial showed that clopidogrel compared with placebo
ight actually be harmful (increased cardiovascular and
verall mortality) in patients with diabetic nephropathy,
laiming the need for additional studies to investigate this
ossible interaction (16).
To the best of our knowledge, this is the first study
roviding a potential underlying mechanism to explain why
M patients with CKD have worse outcomes. The current
harmacodynamic analysis demonstrates a positive relation
etween moderate/severe CKD and HPPR in aspirin-
reated DM patients receiving adjunctive clopidogrel ther-
py. This was confirmed even after adjustment for potential
onfounding factors. In particular, we showed that differ-
nces in platelet reactivity while receiving standard dual
ntiplatelet therapy occurred only in patients with moder-
te/severe CKD, whereas no differences were noted in
atients with mild CKD or normal renal function. Whether
evere CKD is associated with worse outcomes than mod-
rate CKD cannot be addressed by these data, because
atients with moderate or severe CKD were combined into
single group for the purposes of the planned comparisons.
nterestingly, Deray et al. (33) have previously reported in a
mall cohort the lack of difference in platelet response to
lopidogrel between patients with moderate and those with
evere CKD. These observations in aggregate suggest the
resence of a threshold of renal function below which a
reater degree of platelet reactivity occurs. This is in
greement with clinical studies in patients with dual anti-
latelet therapy in which adverse outcomes dramatically
ncreased in patients with more advanced stages of CKD
10,15,16). This also concurs with pharmacodynamic as-
essments, including those conducted in DM patients re-
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Clopidogrel Effects and Renal Function in Diabetes March 16, 2010:1139–46eiving dual antiplatelet therapy, showing that long-term
dverse outcomes markedly increased above a certain
hreshold of platelet reactivity (29,32,34–36).
Although multiple mechanisms have been implied in
eightened platelet reactivity in DM patients, it is unknown
hy the presence of CKD in these patients further adds to
heir degree of platelet dysfunction. Indeed, CKD per se has
een shown to be associated with platelet abnormalities
37–41). However, contrary to pharmacodynamic studies
erformed in DM patients consistently demonstrating
eightened platelet reactivity, reports in CKD patients have
hown contrasting data. In fact, in some of these studies
latelet reactivity was shown to be depressed, whereas in
thers platelet reactivity was shown to be increased (37–41).
hese conflicting findings might be attributed to patient
election, given that the presence of DM—known to have
pecific abnormalities in their platelet biology—was not
pecified.
There has been accumulating data supporting the prog-
ostic implications of HPPR in patients receiving dual
ntiplatelet therapy (27). In particular, HPPR is associated
ith a higher risk of recurrent ischemic events, including
tent thrombosis. Although patients with DM receiving
ual antiplatelet therapy are known to have higher platelet
eactivity compared with non-DM (21,23,25,29), this study
hows a broad variability in their platelet function profiles,
nd the presence of moderate/severe CKD allows for
dentification of those DM patients with greater likelihood
f having HPPR. These pharmacodynamic findings might
Figure 3 Prevalence of Moderate/Severe CKD and Normal Ren
Prevalence of moderate/severe chronic kidney disease (CKD) and normal renal fun
ing to adenosine diphosphate (ADP)- (HPPRADP), collagen- (HPPRCOLL), or both ADP
odds ratio.ontribute to explain why some DM patients have worse autcomes than others and suggest the potential need for
urther categorizing this already high-risk cohort of patients
nto those with and without CKD. This might enable a
etter understanding of their individual risk profile and
llow the future development of targeted treatment strate-
ies for these patients.
The persistence of high platelet reactivity despite adjunc-
ive clopidogrel therapy underscores the need for more
otent platelet inhibiting strategies to reduce recurrent
schemic event risk, including high clopidogrel dosing and
ovel antiplatelet agents (23,42). However, it may be argued
hat high platelet reactivity alone might not be a good indicator
or using more potent platelet inhibition, because their poten-
ial benefit of reducing ischemic events might be offset by
ncreased bleeding rates if CKD is also present. In fact,
mpaired renal function is well-established to be associated
ith increased bleeding risk (12,43–46). This is of clinical
elevance, given that approximately 50% of CKD patients have
M. However, the TRITON–TIMI 38 trial (TRial to Assess
mprovement in Therapeutic Outcomes by Optimizing Plate-
et InhibitioN with Prasugrel–Thrombolysis In Myocardial
nfarction 38) showed that renal failure was not a predictor for
ncreased bleeding in patients treated with prasugrel, a third-
eneration thienopyridine with potent P2Y12 inhibitory effects
47). Importantly, prasugrel achieved its greatest clinical ben-
fit in DM patients without increasing the risk of major
leeding compared with clopidogrel (48). Indeed, evaluating
utcome data in DM patients according to the presence or
nction/Mild CKD in Patients With HPPR
mild CKD in patients with high post-treatment platelet reactivity (HPPR) accord-
ollagen-induced (HPPRADPCOLL) aggregation. CI  confidence interval; OR al Fu
ction/
- and cbsence of CKD will provide more insights on the risk-benefit
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uction of novel and more potent agents.
tudy limitations. This is a cross-sectional study of inde-
endent groups and suffers from the obvious limitations of
nonrandomized trial. In an attempt to account for these
imitations, we also made comparisons that were adjusted
or several clinical variables. Due to the large number of
ariables introduced, we cannot exclude a potential for
verfitting of the model. Furthermore, the independent
ffect of renal function in DM patients with CAD has been
nvestigated while participants were already receiving dual
ntiplatelet therapy. Although absolute platelet reactivity
alues have shown to be of greater prognostic significance
ompared with relative changes (27), the latter could have
rovided more insights on P2Y12 signaling in CKD pa-
ients. Also, factors such as fibrinogen levels have shown to
nfluence platelet reactivity in DM patients (49), but
hether these have an impact in the DM population with
KD was not explored in this study. Therefore, dedicated
tudies are warranted to better understand P2Y12-mediated
ignaling in platelets from CKD patients. Ultimately,
hether the findings of our study can be extrapolated to
KD patients without DM remains unknown.
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